Regulation and Availability

Daval International has developed and patented AIMSPRO, a pharmaceutically produced biological product that is manufactured and processed using a unique specification that is derived from a hyperimmune caprine serum (HICS) source.

AIMSPRO has been used in the effective treatment of patients with Alzheimer’s disease and as result of positive results, will be tested in a randomised clinical trial.

Daval International has acquired validated independent and documented evidence of the basic mechanism of action of AIMSPRO. This mechanism describes biological events that occur as a result of the introduction of AIMSPRO into the human system.

In 2005, AIMSPRO was approved by the MHRA, as a “Special's” medication in the U.K. This allows AIMSPRO to be prescribed by doctors on a named patient basis for ‘unmet medical needs’. Regular orders have been received by Daval from the NHS prescribing the medicine for their patients.

AIMSPRO is also available in Australia under Categories A and B of the Therapeutic Goods Administration’s Special Access Scheme and has been granted Orphan Drug designation in the U.S. and Australia.

Daval International was accepted as a member of the UK’s Association of the British Pharmaceutical Industry (ABPI) in December 2007 and adheres to the APBI's Code of Practice.